Active substance
Results for the substance darunavir+cobicistat
1 result
About this active substance
The combination of darunavir and cobicistat is used in the treatment of human immunodeficiency virus (HIV-1) infection. It is part of antiretroviral therapy and is indicated for adults and adolescents aged 12 years and older who weigh at least 40 kg. The combination helps suppress HIV replication, reducing viral load and maintaining immune system function.
- Darunavir is a protease inhibitor that blocks the HIV protease enzyme, which is essential for processing viral proteins needed for virus replication. By inhibiting this enzyme, darunavir prevents the formation of mature, infectious viral particles, thereby reducing the spread of the virus in the body.
- Cobicistat is a pharmacokinetic enhancer that has no direct antiviral activity but increases the blood concentration of darunavir by inhibiting liver enzymes responsible for its metabolism. This enhances the effectiveness of the treatment, allowing for a lower dose of darunavir.
This combination is administered as a single tablet, taken once daily with food to ensure optimal absorption. It is typically used in combination with other antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs), to form a complete treatment regimen.
While effective, this combination may cause side effects. The most common include nausea, diarrhea, headache, fatigue, and skin rash. In rare cases, more serious reactions such as liver dysfunction, pancreatitis, or severe allergic reactions may occur. Regular monitoring of liver function and overall health is essential for patients on this therapy.
- Darunavir is a protease inhibitor that blocks the HIV protease enzyme, which is essential for processing viral proteins needed for virus replication. By inhibiting this enzyme, darunavir prevents the formation of mature, infectious viral particles, thereby reducing the spread of the virus in the body.
- Cobicistat is a pharmacokinetic enhancer that has no direct antiviral activity but increases the blood concentration of darunavir by inhibiting liver enzymes responsible for its metabolism. This enhances the effectiveness of the treatment, allowing for a lower dose of darunavir.
This combination is administered as a single tablet, taken once daily with food to ensure optimal absorption. It is typically used in combination with other antiretroviral agents, such as nucleoside reverse transcriptase inhibitors (NRTIs), to form a complete treatment regimen.
While effective, this combination may cause side effects. The most common include nausea, diarrhea, headache, fatigue, and skin rash. In rare cases, more serious reactions such as liver dysfunction, pancreatitis, or severe allergic reactions may occur. Regular monitoring of liver function and overall health is essential for patients on this therapy.